Scientists at Kazakh National Agrarian Research University engineered a monoclonal antibody targeting mugwort pollen allergen, delivered intranasally to mice, preventing allergic rhinitis and asthma symptoms upon exposure. Published in Frontiers in Immunology, this approach represents the first in vivo evidence supporting localized antibody therapy against pollen allergens. The study opens pathways for developing personalized, needle-free allergy therapies addressing a significant proportion of the European population affected by hay fever and associated respiratory conditions.